GenMark Responds to the SARS-CoV-2 Outbreak

On March 19, 2020, GenMark Diagnostics announced that the U.S. Food and Drug Administration (FDA) has issued Emergency Use Authorization (EUA) for the company’s ePlex SARS-CoV-2 Test. Read our press release to learn more.

The ePlex® SARS-CoV-2 Test is an automated qualitative nucleic acid multiplex assay designed to detect SARS-CoV-2 nucleic acid in nasopharyngeal swabs collected in viral transport media. This test is performed on the ePlex Sample-to-Answer System capable of automating all aspects of nucleic acid testing including extraction, amplification, and detection in a single-use cartridge.

The ePlex System: The True Sample-to-Answer Solution®

Designed to improve true turnaround time, the ePlex System automates the entire testing process from sample-to-report with the simplest workflow and shortest hands-on time.

ePlex SARS-CoV-2 Test Workflow

Less Than 2 Minutes Hands-On Time

1

Load Sample

2

Load Cartridge

3

Report Results

For More Information



*For use under the Emergency Use Authorization (EUA) only. For in vitro diagnostic use.

popup close button